Thomas Senderovitz
Thomas took over as Director General of the Danish Medicines Agency on 1 April 2016. His career includes more than 20 years working intensively with medicinal products and he has held several senior positions in international biopharmaceutical companies (Ferring Pharmaceuticals, UCB Pharma, Grünenthal GmbH). Most recently, he was a member of the management team of the global contract research organisation PAREXEL engaging in clinical research for pharmaceutical and biotechnological companies. Thomas previously worked at the Clinical Pharmacological Department at Bispebjerg Hospital in Copenhagen. Thomas is a member of EMAs Management Board and Chair of the HMA Management Group. He is member of the Reference Group for Crown Prince Frederik centre for Public Leadership and member of Dataetisk Råd.
Jesper Kjær
Director of Division, Data Analytics Center (DAC). Jesper brings long experience of data handing, analyses and data visualisation having worked in the academic environment and pharmaceutical industry, and he has developed IT systems for the World Health Organization and Rigshospitalet. Jesper has also led the development of risk-based monitoring IT in Novo Nordisk and has headed activities in EU Framework Programmes, TransCelerate Biopharma and HL7.
Anton Pottegård
Professor of pharmacoepidemiology at University of Southern Denmark and ‘head of research’ at Hospital Pharmacy Funen at Odense University Hospital. His research focuses on the use of drugs in its broadest sense. Typically, He uses ´real-world’ data from Danish or international health care registries, to study and identify effects as well as side effects of medicines. Using such data, he has published more than 200 papers in various medical journals.
Moderator: Allan Skaarup Kristensen
Science & Innovation Attaché at Innovation Centre Denmark Silicon Valley / San Francisco. ICDK SV builds bridges and facilitate partnerships between Danish and U.S. companies, research institutions and public stakeholders. Allan has previously worked for the Association of the Pharmaceutical Industry, the Society of Engineers and the Ministry of Higher Education and Science. He has 25 years of experience in the field of research policy and innovation and has in-depth knowledge about strategic planning of public research programs, research funding and foresight methods.